{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:42:24Z","timestamp":1794004944939,"version":"4.8.0"},"reference-count":86,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from nonneoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia by a blast threshold of 20%. The diagnosis of MDS can be challenging because of the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone marrow and peripheral blood morphology, immunophenotyping, and genetic testing. MDS has historically been subdivided into several subtypes by classification schemes, the most recent of which are the International Consensus Classification and World Health Organization Classification (fifth edition), both published in 2022. The aim of MDS classification is to identify entities with shared genetic underpinnings and molecular pathogenesis, and the specific subtype can inform clinical decision-making alongside prognostic risk categorization. The current MDS classification schemes incorporate morphologic features (bone marrow and blood blast percentage, degree of dysplasia, ring sideroblasts, bone marrow fibrosis, and bone marrow hypocellularity) and also recognize 3 entities defined by genetics: isolated del(5q) cytogenetic abnormality, SF3B1 mutation, and TP53 mutation. It is anticipated that with advancing understanding of the genetic basis of MDS pathogenesis, future MDS classification will be based increasingly on genetic classes. Nevertheless, morphologic features in MDS reflect the phenotypic expression of the underlying abnormal genetic pathways and will undoubtedly retain importance to inform prognosis and guide treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2023020078","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T16:30:05Z","timestamp":1696005005000},"page":"2247-2257","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":102,"title":["Diagnosis and classification of myelodysplastic syndromes"],"prefix":"10.1182","volume":"142","author":[{"given":"Robert P.","family":"Hasserjian","sequence":"first","affiliation":[{"name":"1Department of Pathology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Germing","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine University, Dusseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1460-1611","authenticated-orcid":false,"given":"Luca","family":"Malcovati","sequence":"additional","affiliation":[{"name":"3Department of Molecular Medicine, University of Pavia, Pavia, Italy"},{"name":"4Department of Hematology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"25","key":"2023122816270898800_bib1","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2023122816270898800_bib2","doi-asserted-by":"crossref","first-page":"EVIDoa2200310","DOI":"10.1056\/EVIDoa2200310","article-title":"Prediction of risk for myeloid malignancy in clonal hematopoiesis","volume":"2","author":"Weeks","year":"2023","journal-title":"NEJM Evid"},{"issue":"1","key":"2023122816270898800_bib3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood.2019000942","article-title":"Genetics of progression from MDS to secondary leukemia","volume":"136","author":"Menssen","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2023122816270898800_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2021011304","article-title":"Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal","volume":"139","author":"Estey","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2023122816270898800_bib5","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2023122816270898800_bib6","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"2023122816270898800_bib7","doi-asserted-by":"crossref","first-page":"1033534","DOI":"10.3389\/fonc.2022.1033534","article-title":"Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia","volume":"12","author":"Ambinder","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"2023122816270898800_bib8","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00277-014-2252-4","article-title":"Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts","volume":"94","author":"Font","year":"2015","journal-title":"Ann Hematol"},{"issue":"12","key":"2023122816270898800_bib9","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1038\/s41375-021-01328-9","article-title":"Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms","volume":"35","author":"Steensma","year":"2021","journal-title":"Leukemia"},{"issue":"14","key":"2023122816270898800_bib10","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2023122816270898800_bib11","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des Myelodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023122816270898800_bib12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1053\/j.semdp.2023.04.006","article-title":"Pediatric myelodysplastic syndrome","volume":"40","author":"Babcock","year":"2023","journal-title":"Semin Diagn Pathol"},{"issue":"17","key":"2023122816270898800_bib13","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","article-title":"Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet","volume":"122","author":"Malcovati","year":"2013","journal-title":"Blood"},{"issue":"43","key":"2023122816270898800_bib14","doi-asserted-by":"crossref","first-page":"73483","DOI":"10.18632\/oncotarget.19008","article-title":"Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions","volume":"8","author":"Valent","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"2023122816270898800_bib15","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.leukres.2006.11.009","article-title":"Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference","volume":"31","author":"Valent","year":"2007","journal-title":"Leuk Res"},{"issue":"5","key":"2023122816270898800_bib16","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/hon.2777","article-title":"Kinetics of pre-myelodysplastic syndromes blood values correlate with disease risk and survival","volume":"38","author":"Joffe","year":"2020","journal-title":"Hematol Oncol"},{"issue":"16","key":"2023122816270898800_bib17","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1182\/blood-2016-07-728766","article-title":"Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes","volume":"128","author":"Greenberg","year":"2016","journal-title":"Blood"},{"issue":"24","key":"2023122816270898800_bib18","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1182\/blood.2019001610","article-title":"Clinical utility of targeted next-generation sequencing-based screening of peripheral blood in the evaluation of cytopenias","volume":"134","author":"Shanmugam","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2023122816270898800_bib19","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood.2021011323","article-title":"Relationship between clone metrics and clinical outcome in clonal cytopenia","volume":"138","author":"Galli","year":"2021","journal-title":"Blood"},{"issue":"14","key":"2023122816270898800_bib20","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1182\/bloodadvances.2022008578","article-title":"Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions","volume":"7","author":"DeZern","year":"2023","journal-title":"Blood Adv"},{"issue":"21","key":"2023122816270898800_bib21","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1182\/bloodadvances.2021004755","article-title":"A\u00a0geno-clinical decision model for the diagnosis of myelodysplastic syndromes","volume":"5","author":"Radakovich","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"2023122816270898800_bib22","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11899-012-0140-3","article-title":"Dysplasia has a differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors","volume":"7","author":"Steensma","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"issue":"6","key":"2023122816270898800_bib23","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.leukres.2012.02.014","article-title":"Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Dusseldorf Registry on myelodysplastic syndromes","volume":"36","author":"Germing","year":"2012","journal-title":"Leuk Res"},{"key":"2023122816270898800_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-3-030-51878-3_2","volume-title":"Diagnosis and Management of Myelodysplastic Syndromes: A Clinical Guide","author":"Goel","year":"2020"},{"issue":"4","key":"2023122816270898800_bib25","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2141.2008.07505.x","article-title":"The role of X-inactivation in the gender bias of patients with acquired alpha-thalassaemia and myelodysplastic syndrome (ATMDS)","volume":"144","author":"Haas","year":"2009","journal-title":"Br J Haematol"},{"issue":"8","key":"2023122816270898800_bib26","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/ajh.24073","article-title":"Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis","volume":"90","author":"Herbaux","year":"2015","journal-title":"Am J Hematol"},{"issue":"7","key":"2023122816270898800_bib27","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3324\/haematol.2008.005421","article-title":"Morphological evaluation of monocytes and their precursors","volume":"94","author":"Goasguen","year":"2009","journal-title":"Haematologica"},{"issue":"17","key":"2023122816270898800_bib28","first-page":"2047","article-title":"Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2023122816270898800_bib29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminhematol.2018.05.015","article-title":"The current approach to the diagnosis of myelodysplastic syndromes\u2606","volume":"56","author":"Weinberg","year":"2019","journal-title":"Semin Hematol"},{"issue":"2","key":"2023122816270898800_bib30","first-page":"79","article-title":"Enumeration of CD34+ blasts by immunohistochemistry in bone marrow biopsies from MDS patients may have significant impact on final WHO classification","volume":"13","author":"Saft","year":"2020","journal-title":"J\u00a0Hematop"},{"issue":"1","key":"2023122816270898800_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/cyto.b.22108","article-title":"Multiparameter flow cytometry in the evaluation of myelodysplasia: analytical issues: recommendations from the European LeukemiaNet\/International Myelodysplastic Syndrome Flow Cytometry Working Group","volume":"104","author":"Porwit","year":"2023","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"2023122816270898800_bib32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cyto.b.22044","article-title":"Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: a report of the European LeukemiaNet International MDS-Flow Cytometry Working Group","volume":"104","author":"van de Loosdrecht","year":"2023","journal-title":"Cytometry B Clin Cytom"},{"issue":"21","key":"2023122816270898800_bib33","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1182\/bloodadvances.2017011197","article-title":"Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia","volume":"1","author":"Morgan","year":"2017","journal-title":"Blood Adv"},{"issue":"2","key":"2023122816270898800_bib34","doi-asserted-by":"crossref","first-page":"106","DOI":"10.6004\/jnccn.2022.0009","article-title":"NCCN Guidelines(R) Insights: myelodysplastic syndromes, version 3.2022","volume":"20","author":"Greenberg","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"13","key":"2023122816270898800_bib35","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1182\/blood-2007-03-082404","article-title":"New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients","volume":"110","author":"Haase","year":"2007","journal-title":"Blood"},{"issue":"15","key":"2023122816270898800_bib36","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2010.28.3978","article-title":"Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system","volume":"29","author":"Schanz","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023122816270898800_bib37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/gcc.23107","article-title":"The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high-risk clonal cytopenia of unknown significance","volume":"62","author":"Brett","year":"2023","journal-title":"Genes Chromosomes Cancer"},{"issue":"21","key":"2023122816270898800_bib38","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2023122816270898800_bib39","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.leukres.2005.01.019","article-title":"Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529\u00a0patients","volume":"29","author":"Steidl","year":"2005","journal-title":"Leuk Res"},{"issue":"7","key":"2023122816270898800_bib40","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"10","key":"2023122816270898800_bib41","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"issue":"10","key":"2023122816270898800_bib42","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1182\/blood-2016-10-745273","article-title":"Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy","volume":"129","author":"Duncavage","year":"2017","journal-title":"Blood"},{"issue":"18","key":"2023122816270898800_bib43","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1182\/bloodadvances.2020002306","article-title":"Mutational analysis of hematologic neoplasms in 164 paired peripheral blood and bone marrow samples by next-generation sequencing","volume":"4","author":"Lucas","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"2023122816270898800_bib44","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.3390\/cancers15082305","article-title":"Myeloid NGS analyses of paired samples from bone marrow and peripheral blood yield concordant results: a prospective cohort analysis of the AGMT Study Group","volume":"15","author":"Jansko-Gadermeir","year":"2023","journal-title":"Cancers"},{"issue":"11","key":"2023122816270898800_bib45","doi-asserted-by":"crossref","first-page":"E420","DOI":"10.1002\/ajh.26325","article-title":"Myelodysplastic syndromes with no somatic mutations detected by next-generation sequencing display similar features to myelodysplastic syndromes with detectable mutations","volume":"96","author":"Wang","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"2023122816270898800_bib46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00428-022-03417-1","article-title":"The International Consensus Classification of myelodysplastic syndromes and related entities","volume":"482","author":"Hasserjian","year":"2023","journal-title":"Virchows Arch"},{"issue":"21","key":"2023122816270898800_bib47","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1182\/blood-2015-08-667063","article-title":"MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance","volume":"126","author":"Kwok","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2023122816270898800_bib48","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1182\/blood-2015-08-663237","article-title":"Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression","volume":"126","author":"Cargo","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2023122816270898800_bib49","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood.2022019304","article-title":"Prevalence and clinical expression of germline predisposition to myeloid neoplasms in adults with marrow hypocellularity","volume":"142","author":"Molteni","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2023122816270898800_bib50","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00428-022-03447-9","article-title":"The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia","volume":"482","author":"Rudelius","year":"2023","journal-title":"Virchows Arch"},{"issue":"2","key":"2023122816270898800_bib51","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/MOH.0000000000000633","article-title":"Germline mutations in MDS\/AML predisposition disorders","volume":"28","author":"Godley","year":"2021","journal-title":"Curr Opin Hematol"},{"issue":"24","key":"2023122816270898800_bib52","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood.2022015790","article-title":"Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages","volume":"140","author":"Feurstein","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2023122816270898800_bib53","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1038\/s41375-022-01729-4","article-title":"Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia","volume":"36","author":"Kubota","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"2023122816270898800_bib54","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1038\/s41375-021-01137-0","article-title":"Germline variants drive myelodysplastic syndrome in young adults","volume":"35","author":"Feurstein","year":"2021","journal-title":"Leukemia"},{"issue":"14","key":"2023122816270898800_bib55","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2016-05-670240","article-title":"How I diagnose and manage individuals at risk for inherited myeloid malignancies","volume":"128","author":"The University of Chicago Hematopoietic Malignancies Cancer Risk Team","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2023122816270898800_bib56","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2017-02-735290","article-title":"Genetic predisposition to hematologic malignancies: management and surveillance","volume":"130","author":"Godley","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2023122816270898800_bib57","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood.2020006910","article-title":"Identifying potential germline variants from sequencing hematopoietic malignancies","volume":"136","author":"Kraft","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2023122816270898800_bib58","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41436-020-0934-y","article-title":"Assessment of technical heterogeneity among diagnostic tests to detect germline risk variants for hematopoietic malignancies","volume":"23","author":"Roloff","year":"2021","journal-title":"Genet Med"},{"issue":"17","key":"2023122816270898800_bib59","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood.2019000909","article-title":"Germline DDX41 mutations define a significant entity within adult MDS\/AML patients","volume":"134","author":"Sebert","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2023122816270898800_bib60","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2022018221","article-title":"Germ line DDX41 mutations define a unique subtype of myeloid neoplasms","volume":"141","author":"Makishima","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2023122816270898800_bib61","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"issue":"12","key":"2023122816270898800_bib62","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0145-2126(00)00088-6","article-title":"Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients","volume":"24","author":"Germing","year":"2000","journal-title":"Leuk Res"},{"issue":"4","key":"2023122816270898800_bib63","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1046\/j.1365-2141.2000.01940.x","article-title":"Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction","volume":"108","author":"Germing","year":"2000","journal-title":"Br J Haematol"},{"issue":"5","key":"2023122816270898800_bib64","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0145-2126(92)90171-3","article-title":"Heterogeneity of acquired idiopathic sideroblastic anaemia (AISA)","volume":"16","author":"Garand","year":"1992","journal-title":"Leuk Res"},{"issue":"1","key":"2023122816270898800_bib65","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood.V74.1.395.395","article-title":"Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients","volume":"74","author":"Sanz","year":"1989","journal-title":"Blood"},{"key":"2023122816270898800_bib66","first-page":"61","volume-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Brunning","year":"2001"},{"key":"2023122816270898800_bib67","first-page":"88","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Brunning","year":"2008"},{"issue":"2","key":"2023122816270898800_bib68","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/MOH.0000000000000404","article-title":"Changes in the World Health Organization 2016 classification of myeloid neoplasms everyone should know","volume":"25","author":"Hasserjian","year":"2018","journal-title":"Curr Opin Hematol"},{"issue":"11","key":"2023122816270898800_bib69","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood.2022015849","article-title":"Developing a classification of hematologic neoplasms in the era of precision medicine","volume":"140","author":"Cazzola","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2023122816270898800_bib70","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1038\/s41375-022-01724-9","article-title":"Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes","volume":"36","author":"Zeidan","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"2023122816270898800_bib71","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/bloodadvances.2022008747","article-title":"An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS","volume":"7","author":"Stahl","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2023122816270898800_bib72","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ajh.26812","article-title":"Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia","volume":"98","author":"Falini","year":"2023","journal-title":"Am J Hematol"},{"issue":"8","key":"2023122816270898800_bib73","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1200\/JCO.22.02680","article-title":"What is in a name? Consequences of the classification schism in hematopathology","volume":"41","author":"Aster","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"2023122816270898800_bib74","doi-asserted-by":"crossref","first-page":"106611","DOI":"10.1016\/j.leukres.2021.106611","article-title":"Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral center","volume":"108","author":"Nachtkamp","year":"2021","journal-title":"Leuk Res"},{"issue":"3","key":"2023122816270898800_bib75","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41375-020-0917-7","article-title":"Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS","volume":"35","author":"Kuendgen","year":"2021","journal-title":"Leukemia"},{"issue":"10","key":"2023122816270898800_bib76","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3324\/haematol.2017.167726","article-title":"Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation","volume":"102","author":"Kanagal-Shamanna","year":"2017","journal-title":"Haematologica"},{"issue":"20","key":"2023122816270898800_bib77","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1182\/blood.2020005488","article-title":"Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes","volume":"136","author":"Nagata","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2023122816270898800_bib78","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.20.01659","article-title":"Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes","volume":"39","author":"Bersanelli","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023122816270898800_bib79","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41375-023-01855-7","article-title":"MDS subclassification-do we still have to count blasts?","volume":"37","author":"Huber","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2023122816270898800_bib80","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1038\/s41467-023-38515-4","article-title":"Molecular patterns identify distinct subclasses of myeloid neoplasia","volume":"14","author":"Kewan","year":"2023","journal-title":"Nat Commun"},{"issue":"5","key":"2023122816270898800_bib81","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bpa.12171","article-title":"International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading","volume":"24","author":"Louis","year":"2014","journal-title":"Brain Pathol"},{"issue":"10","key":"2023122816270898800_bib82","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa2024534","article-title":"Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers","volume":"384","author":"Duncavage","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"2023122816270898800_bib83","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood.2021014309","article-title":"Guiding the global evolution of cytogenetic testing for hematologic malignancies","volume":"139","author":"Akkari","year":"2022","journal-title":"Blood"},{"issue":"24","key":"2023122816270898800_bib84","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1182\/blood-2015-08-664649","article-title":"Integrated genomic DNA\/RNA profiling of hematologic malignancies in the clinical setting","volume":"127","author":"He","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2023122816270898800_bib85","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"7834","key":"2023122816270898800_bib86","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/26\/2247\/2178049\/blood_bld-2023-020078-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/26\/2247\/2178049\/blood_bld-2023-020078-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T11:27:51Z","timestamp":1703762871000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/26\/2247\/498176\/Diagnosis-and-classification-of-myelodysplastic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":86,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2023,12,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023020078","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,28]]}}}